When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6277
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia ; volume:19 ; number:3 ; day:8 ; month:3 ; year:2018 ; pages:1-13 ; date:3.2018
Current treatment options in oncology ; 19, Heft 3 (8.3.2018), 1-13, 3.2018
- Creator
-
Laneuville, Pierre
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-018-0532-2
- URN
-
urn:nbn:de:1111-201805218317
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Laneuville, Pierre
- SpringerLink (Online service)
Other Objects (12)
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia